Cognitive outcomes of prenatal antiepileptic drug exposure

Epilepsy Research

Volumn 114, Issue , 2015, Pages 89-97

  Inoyama, Katherine ^a   Meador, Kimford J ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Antiepileptic drugs; Cognitive; Epilepsy; Pregnancy; Teratogen

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ESTRADIOL; ETIRACETAM; LAMOTRIGINE; MAGNESIUM SULFATE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID; VINPOCETINE; TERATOGENIC AGENT;

APOPTOSIS; AUTISM; BEHAVIOR DISORDER; BREAST FEEDING; CEREBRAL PALSY; COGNITIVE DEFECT; CONGENITAL MALFORMATION; DEMENTIA; DEVELOPMENTAL DISORDER; ECLAMPSIA; FETUS OUTCOME; GENERALIZED EPILEPSY; HIGH RISK INFANT; HUMAN; HYPERACTIVITY; INTELLIGENCE QUOTIENT; LEARNING DISORDER; LONG TERM EXPOSURE; LOW BIRTH WEIGHT; MEMORY DISORDER; MONOTHERAPY; MOTOR DYSFUNCTION; NEUROPROTECTION; NONHUMAN; NUCLEUS ACCUMBENS; OUTCOME ASSESSMENT; POLYPHARMACY; PREGNANCY DISORDER; PREMATURE LABOR; PREMATURITY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TERATOGENICITY; ADULT; CHEMICALLY INDUCED; COGNITION; COGNITION DISORDERS; DRUG EFFECTS; FEMALE; PREGNANCY; PRENATAL EXPOSURE; PSYCHOLOGY;

ADULT; ANTICONVULSANTS; COGNITION; COGNITION DISORDERS; FEMALE; HUMANS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; TERATOGENS;

EID: 84931072059     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2015.04.016     Document Type: Review

References (76)

1. Åberg E., Holst S., Neagu A., Ögren S.O., Lavebratt C. Prenatal exposure to carbamazepine reduces hippocampal and cortical neuronal cell population in new-born and young mice without detectable effects on learning and memory. PLOS ONE 2013, 8:e80497.
2. Adab N., Kini U., Vinten J., Ayres J., Baker G., Clayton-Smith J., Coyle H., Fryer A., Gorry J., Gregg J., Mawer G., Nicolaides P., Pickering L., Tunnicliffe L., Chadwick D.W. The longer term outcome of children born to mothers with epilepsy. J. Neurol. Neurosurg. Psychiatry 2004, 75:1575-1583.
3. Asimiadou S., Bittigau P., Felderhoff-Mueser U., Manthey D., Sifringer M., Pesditschek S., Dzietko M., Kaindl A.M., Pytel M., Studniarczyk D., Mozrzymas J.W., Ikonomidou C. Protection with estradiol in developmental models of apoptotic neurodegeneration. Ann. Neurol. 2005, 58:266-276.
4. Baker G.A., Bromley R.L., Briggs M., Cheyne C.P., Cohen M.J., García-Fiñana M., Gummery A., Kneen R., Loring D.W., Mawer G., Meador K.J., Shallcross R., Clayton-Smith J. IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study. Neurology 2015, 84:382-390. On behalf of the Liverpool and Manchester Neurodevelopment Group.
5. Bittigau P., Sifringer M., Genz K., Reith E., Pospischil D., Govindarajalu S., Dzietko M., Pesditschek S., Mai I., Dikranian K., Olney J.W., Ikonomidou C. Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:15089-15094.
6. Bittigau P., Sifringer M., Ikonomidou C. Antiepileptic drugs and apoptosis in the developing brain. Ann. N. Y. Acad. Sci. 2003, 993:103-114.
7. Bromley R.L., Mawer G.E., Briggs M., Cheyne C., Clayton-Smith J., García-Fiñana M., Kneen R., Lucas S.B., Shallcross R., Baker G.A. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. J. Neurol. Neurosurg. Psychiatry 2013, 84:637-643. Liverpool and Manchester Neurodevelopment Group.
8. Chollat C., Enser M., Houivet E., Provost D., Bénichou J., Marpeau L., Marret S. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. J. Pediatr. 2014, 165:398-400.
9. Christensen J., Grønborg T.K., Sørensen M.J., Schendel D., Parner E.T., Pedersen L.H., Vestergaard M. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 2013, 309:1696-1703.
10. Conde-Agudelo A., Romero R. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis. Am. J. Obstet. Gynecol. 2009, 200:595-609.
11. Doyle L.W., Crowther C.A., Middleton P., Marret S. Antenatal magnesium sulfate and neurologic outcome in preterm infants: a systematic review. Obstet. Gynecol. 2009, 113:1327-1333.
12. Doyle L.W., Anderson P.J., Haslam R., Lee K.J., Crowther C. School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs. placebo. JAMA 2014, 312:1105-1113. Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Study Group.
13. Dribben W.H., Eisenman L.N., Mennerick S. Magnesium induces neuronal apoptosis by suppressing excitability. Cell Death Dis. 2010, 1:e63.
14. Eriksson K., Viinikainen K., Mönkkönen A., Aikiä M., Nieminen P., Heinonen S., Kälviäinen R. Children exposed to valproate in utero - population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Res. 2005, 65:189-200.
15. Filgueiras C.C., Krahe T.E., Medina A.E. Phosphodiesterase type 1 inhibition improves learning in rats exposed to alcohol during the third trimester equivalent of human gestation. Neurosci. Lett. 2010, 473:202-207.
16. Forcelli P.A., Kim J., Kondratyev A., Gale K. Pattern of antiepileptic drug-induced cell death in limbic regions of the neonatal rat brain. Epilepsia 2011, 52:e207-e211.
17. Forcelli P.A., Janssen M.J., Vicini S., Gale K. Neonatal exposure to antiepileptic drugs disrupts striatal synaptic development. Ann. Neurol. 2012, 72:363-372.
18. Franks M.E., Macpherson G.R., Figg W.D. Thalidomide. Lancet 2004, 363:1802-1811.
19. Gaily E., Kantola-Sorsa E., Granström M.L. Intelligence of children of epileptic mothers. J. Pediatr. 1988, 113:677-684.
20. Gaily E., Kantola-Sorsa E., Hiilesmaa V., Isoaho M., Matila R., Kotila M., Nylund T., Bardy A., Kaaja E., Granström M.L. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 2004, 62:28-32.
21. Glier C., Dzietko M., Bittigau P., Jarosz B., Korobowicz E., Ikonomidou C. Therapeutic doses of topiramate are not toxic to the developing rat brain. Exp. Neurol. 2004, 187:403-409.
22. Hanson J.W., Myrianthopoulos N.C., Harvey M.A., Smith D.W. Risks to the offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. J. Pediatr. 1976, 89:662-668.
23. Harden C.L., Meador K.J., Pennell P.B., Hauser W.A., Gronseth G.S., French J.A., Wiebe S., Thurman D., Koppel B.S., Kaplan P.W., Robinson J.N., Hopp J., Ting T.Y., Gidal B., Hovinga C.A., Wilner A.N., Vazquez B., Holmes L., Krumholz A., Finnell R., Hirtz D., Le Guen C. Practice parameter update: management issues for women with epilepsy-focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009, 73:133-141. American Academy of Neurology; American Epilepsy Society.
24. Hill R.M., Verniaud W.M., Horning M.G., McCulley L.B., Morgan N.F. Infants exposed in utero to antiepileptic drugs. a prospective study. Am. J. Dis. Child 1974, 127:645-653.
25. Hirano T., Fujioka K., Okada M., Iwasa H., Kaneko S. Physical and psychomotor development in the offspring born to mothers with epilepsy. Epilepsia 2004, 45(Suppl. 8):53-57.
26. Holmes L.B., Rosenberger P.B., Harvey E.A., Khoshbin S., Ryan L. Intelligence and physical features of children of women with epilepsy. Teratology 2000, 61:196-202.
27. Ikonomidou C., Scheer I., Wilhelm T., Juengling F.D., Titze K., Stöver B., Lehmkuhl U., Koch S., Kassubek J. Brain morphology alterations in the basal ganglia and the hypothalamus following prenatal exposure to antiepileptic drugs. Eur. J. Paediatr. Neurol. 2007, 11:297-301.
28. Katz I., Kim J., Gale K., Kondratyev A. Effects of lamotrigine alone and in combination with MK-801, phenobarbital, or phenytoin on cell death in the neonatal rat brain. J. Pharmacol. Exp. Ther. 2007, 322:494-500.
29. Kim J., Kondratyev A., Gale K. Antiepileptic drug-induced neuronal cell death in the immature brain: effects of carbamazepine, topiramate, and levetiracetam as monotherapy versus polytherapy. J. Pharmacol. Exp. Ther. 2007, 323:165-173.
30. Kim J.S., Kondratyev A., Tomita Y., Gale K. Neurodevelopmental impact of antiepileptic drugs and seizures in the immature brain. Epilepsia 2007, 48(Suppl. 5):19-26.
31. Koch S., Titze K., Zimmermann R.B., Schröder M., Lehmkuhl U., Rauh H. Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia 1999, 40:1237-1243.
32. Lösche G., Steinhausen H.C., Koch S., Helge H. The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatr. 1994, 83:961-966.
33. Manent J.B., Jorquera I., Mazzucchelli I., Depaulis A., Perucca E., Ben-Ari Y., Represa A. Fetal exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias. Epilepsia 2007, 48:684-693.
34. Manthey D., Asimiadou S., Stefovska V., Kaindl A.M., Fassbender J., Ikonomidou C., Bittigau P. Sulthiame but not levetiracetam exerts neurotoxic effect in the developing rat brain. Exp. Neurol. 2005, 193:497-503.
35. Meador K.J., Gevins A., Loring D.W., McEvoy L.K., Ray P.G., Smith M.E., Motamedi G.K., Evans B.M., Baum C. Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam. Neurology 2007, 69:2076-2084.
36. Meador K.J., Baker G.A., Browning N., Clayton-Smith J., Combs-Cantrell D.T., Cohen M., Kalayjian L.A., Kanner A., Liporace J.D., Pennell P.B., Privitera M., Loring D.W. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N. Engl. J. Med. 2009, 360:1597-1605. NEAD Study Group.
37. Meador K.J., Baker G.A., Browning N., Cohen M.J., Clayton-Smith J., Kalayjian L.A., Kanner A., Liporace J.D., Pennell P.B., Privitera M., Loring D.W. Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain 2011, 134:396-404. NEAD Study Group.
38. Meador K.J., Baker G.A., Browning N., Clayton-Smith J., Cohen M.J., Kalayjian L.A., Kanner A., Liporace J.D., Pennell P.B., Privitera M., Loring D.W. Relationship of child IQ to parental IQ and education in children with fetal antiepileptic drug exposure. Epilepsy Behav. 2011, 21:147-152.
39. Meador K.J., Baker G.A., Browning N., Cohen M.J., Bromley R.L., Clayton-Smith J., Kalayjian L.A., Kanner A., Liporace J.D., Pennell P.B., Privitera M., Loring D.W. Effects of fetal antiepileptic drug exposure: outcomes at age 4.5 years. Neurology 2012, 78:1207-1214. NEAD Study Group.
40. Meador K.J., Baker G.A., Browning N., Cohen M.J., Bromley R.L., Clayton-Smith J., Kalayjian L.A., Kanner A., Liporace J.D., Pennell P.B., Privitera M., Loring D.W. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013, 12:244-252. NEAD Study Group.
41. Meador K.J., Baker G.A., Browning N., Cohen M.J., Bromley R.L., Clayton-Smith J., Kalayjian L.A., Kanner A., Liporace J.D., Pennell P.B., Privitera M., Loring D.W. Breastfeeding in children of women taking antiepileptic drugs: cognitive outcomes at age 6 years. JAMA Pediatr. 2014, 168:729-736. Neurodevelopmental Effects of Antiepileptic Drugs (NEAD) Study Group.
42. Meadow S.R. Anticonvulsant drugs and congenital abnormalities. Lancet 1968, 2:1296.
43. Medina A.E., Krahe T.E., Ramoa A.S. Restoration of neuronal plasticity by a phosphodiesterase type 1 inhibitor in a model of fetal alcohol exposure. J. Neurosci. 2006, 26:1057-1060.
44. Millar J.H., Nevin N.C. Congenital malformations and anticonvulsant drugs. Lancet 1973, 1:328.
45. Motamedi G.K., Meador K.J. Antiepileptic drugs and memory. Epilepsy Behav. 2004, 5:435-439.
46. Mowery T.M., McDowell A.L., Garraghty P.E. Chronic developmental exposure to phenytoin has long-term behavioral consequences. Int. J. Dev. Neurosci. 2008, 26:401-407.
47. Odsbu I., Skurtveit S., Selmer R., Roth C., Hernandez-Diaz S., Handal M. Prenatal exposure to anxiolytics and hypnotics and language competence at 3 years of age. Eur. J. Clin. Pharmacol. 2014, (Epub ahead of print).
48. Ogura H., Yasuda M., Nakamura S., Yamashita H., Mikoshiba K., Ohmori H. Neurotoxic damage of granule cells in the dentate gyrus and the cerebellum and cognitive deficit following neonatal administration of phenytoin in mice. J. Neuropathol. Exp. Neurol. 2002, 61:956-967.
49. Ornoy A., Cohen E. Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Arch. Dis. Child 1996, 75:517-520.
50. Phillips N.K., Lockard J.S. Phenytoin and/or stiripentol in pregnancy: infant monkey hyperexcitability. Epilepsia 1993, 34:1117-1122.
51. Phillips N.K., Lockard J.S. Infant monkey hyperexcitability after prenatal exposure to antiepileptic compounds. Epilepsia 1996, 37:991-999.
52. Rasalam A.D., Hailey H., Williams J.H., Moore S.J., Turnpenny P.D., Lloyd D.J., Dean J.C. Characteristics of fetal anticonvulsant syndrome associated autistic disorder. Dev. Med. Child Neurol. 2005, 47:551-555.
53. Reinisch J.M., Sanders S.A., Mortensen E.L., Rubin D.B. In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA 1995, 274:1518-1525.
54. Rihtman T., Parush S., Ornoy A. Preliminary findings of the developmental effects of in utero exposure to topiramate. Reprod. Toxicol. 2012, 34:308-311.
55. Rogel-Fuchs Y., Newman M.E., Trombka D., Zahalka E.A., Yanai J. Hippocampal cholinergic alterations and related behavioral deficits after early exposure to phenobarbital. Brain Res. Bull. 1992, 29:1-6.
56. Roullet F.I., Lai J.K., Foster J.A. In utero exposure to valproic acid and autism - a current review of clinical and animal studies. Neurotoxicol. Teratol. 2013, 36:47-56.
57. Schilling M.A., Inman S.L., Morford L.L., Moran M.S., Vorhees C.V. Prenatal phenytoin exposure and spatial navigation in offspring: effects on reference and working memory and on discrimination learning. Neurotoxicol. Teratol. 1999, 21:567-578.
58. Schneider T., Przewlocki R. Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology 2005, 30:80-89.
59. Scolnik D., Nulman I., Rovet J., Gladstone D., Czuchta D., Gardner H.A., Gladstone R., Ashby P., Weksberg R., Einarson T., Koren G. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 1994, 271:767-770.
60. Shallcross R., Bromley R.L., Irwin B., Bonnett L.J., Morrow J., Baker G.A. Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology 2011, 76:383-389. Liverpool Manchester Neurodevelopment Group; UK Epilepsy and Pregnancy Register.
61. Shallcross R., Bromley R.L., Cheyne C.P., García-Fiñana M., Irwin B., Morrow J., Baker G.A. In utero exposure to levetiracetam vs valproate: development and language at 3 years of age. Neurology 2014, 82:213-221. Liverpool and Manchester Neurodevelopment Group; UK Epilepsy and Pregnancy Register.
62. Shapiro S., Hartz S.C., Siskind V., Mitchell A.A., Slone D., Rosenberg L., Monson R.R., Heinonen O.P. Anticonvulsants and parental epilepsy in the development of birth defects. Lancet 1976, 1:272-275.
63. Sitges M., Sanchez-Tafolla B.M., Chiu L.M., Aldana B.I., Guarneros A. Vinpocetine inhibits glutamate release induced by the convulsive agent 4-aminopyridine more potently than several antiepileptic drugs. Epilepsy Res. 2011, 96:257-266.
64. Speidel B.D., Meadow S.R. Maternal epilepsy and abnormalities of the fetus and newborn. Lancet 1972, 2:839-843.
65. Steinhausen H.C., Nestler V., Huth H. Psychopathology and mental functions in the offspring of alcoholic and epileptic mothers. J. Am. Acad. Child Psychiatry 1982, 21:268-273.
66. Steinhausen H.C., Lösche G., Koch S., Helge H. The psychological development of children of epileptic parents. I. Study design and comparative findings. Acta Paediatr. 1994, 83:955-960.
67. Szatmari S.Z., Whitehouse P.J. Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst. Rev. 2003, 1. CD003119.
68. Vanoverloop D., Schnell R.R., Harvey E.A., Holmes L.B. The effects of prenatal exposure to phenytoin and other anticonvulsants on intellectual function at 4 to 8 years of age. Neurotoxicol. Teratol. 1992, 14:329-335.
69. Veiby G., Engelsen B.A., Gilhus N.E. Early child development and exposure to antiepileptic drugs prenatally and through breastfeeding: a prospective cohort study on children of women with epilepsy. JAMA Neurol. 2013, 70:1367-1374.
70. Viggedal G., Hagberg B.S., Laegreid L., Aronsson M. Mental development in late infancy after prenatal exposure to benzodiazepines - a prospective study. J. Child Psychol. Psychiatry 1993, 34:295-305.
71. Vinten J., Adab N., Kini U., Gorry J., Gregg J., Baker G.A. Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology 2005, 64:949-954. Liverpool and Manchester Neurodevelopment Study Group.
72. Vorhees C.V. Fetal hydantoin syndrome in rats: dose-effect relationships of prenatal phenytoin on postnatal development and behavior. Teratology 1987, 35:287-303.
73. Vorhees C.V., Rauch S.L., Hitzemann R.J. Prenatal phenytoin exposure decreases neuronal membrane order in rat offspring hippocampus. Int. J. Dev. Neurosci. 1990, 8:283-288.
74. Vorhees C.V., Rauch S.L., Hitzemann R.J. Prenatal valproic acid exposure decreases neuronal membrane order in rat offspring hippocampus and cortex. Neurotoxicol. Teratol. 1991, 13:471-474.
75. Weisenburger W.P., Minck D.R., Acuff K.D., Vorhees C.V. Dose-response effects of prenatal phenytoin exposure in rats: effects on early locomotion, maze learning, and memory as a function of phenytoin-induced circling behavior. Neurotoxicol. Teratol. 1990, 12:145-152.
76. Wide K., Henning E., Tomson T., Winbladh B. Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatr. 2002, 91:409-414.